A cross-indication biomarker analysis is underway to compare the immune microenvironments of responsive and non-responsive tumors (for example, melanoma versus NSCLC/ESCC), with the aim of elucidating determinants of heterogeneity in patient response to dual PD-1/LAG-3 blockade. This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.